Overview
- A Nature Communications Article-in-Press published on Dec. 12 details vaccine candidates that display redesigned filovirus glycoproteins on self-assembling protein nanoparticles.
- Biochemical and structural analyses confirmed correct nanoparticle assembly and accurate antigen presentation.
- In mouse studies, the candidates generated strong, cross-reactive neutralizing antibodies against several filoviruses.
- Targeted modification of surface glycans exposed conserved epitopes that are typically hidden by the mucin and glycan shield.
- The team plans to extend the structure-guided nanoparticle approach to Lassa and Nipah viruses, with support from the NIH and Scripps spin-off Uvax Bio.